Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 253

1.

Propranolol exhibits activity against hemangiomas independent of beta blockade.

Sasaki M, North PE, Elsey J, Bubley J, Rao S, Jung Y, Wu S, Zou MH, Pollack BP, Kumar J, Singh H, Arbiser JL.

NPJ Precis Oncol. 2019 Nov 1;3:27. doi: 10.1038/s41698-019-0099-9. eCollection 2019.

2.

Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma in vivo.

Musi E, Schwartz GK, Yoo JH, Odelberg SJ, Li DY, Bonner MY, Selvakumar P, Rao S, Gilbert LC, Elsey J, Arbiser JL.

Oncotarget. 2019 Jul 8;10(43):4424-4436. doi: 10.18632/oncotarget.27040. eCollection 2019 Jul 8.

3.

Topical Application of Cinnamaldehyde Promotes Faster Healing of Skin Wounds Infected with Pseudomonas aeruginosa.

Ferro TAF, Souza EB, Suarez MAM, Rodrigues JFS, Pereira DMS, Mendes SJF, Gonzaga LF, Machado MCAM, Bomfim MRQ, Calixto JB, Arbiser JL, Monteiro-Neto V, André E, Fernandes ES.

Molecules. 2019 Apr 25;24(8). pii: E1627. doi: 10.3390/molecules24081627.

4.

Palladium based nanoparticles for the treatment of advanced melanoma.

Elsey J, Bubley JA, Zhu L, Rao S, Sasaki M, Pollack BP, Yang L, Arbiser JL.

Sci Rep. 2019 Mar 1;9(1):3255. doi: 10.1038/s41598-019-40258-6.

5.

Myofibroblast proliferation and heterogeneity are supported by macrophages during skin repair.

Shook BA, Wasko RR, Rivera-Gonzalez GC, Salazar-Gatzimas E, López-Giráldez F, Dash BC, Muñoz-Rojas AR, Aultman KD, Zwick RK, Lei V, Arbiser JL, Miller-Jensen K, Clark DA, Hsia HC, Horsley V.

Science. 2018 Nov 23;362(6417). pii: eaar2971. doi: 10.1126/science.aar2971.

6.

Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and β-catenin pathways.

Chiu CS, Tsai CH, Hsieh MS, Tsai SC, Jan YJ, Lin WY, Lai DW, Wu SM, Hsing HY, Arbiser JL, Sheu ML.

Cancer Lett. 2019 Feb 1;442:113-125. doi: 10.1016/j.canlet.2018.10.026. Epub 2018 Nov 1.

PMID:
30391358
7.

Antioxidants: Positive or Negative Actors?

Salehi B, Martorell M, Arbiser JL, Sureda A, Martins N, Maurya PK, Sharifi-Rad M, Kumar P, Sharifi-Rad J.

Biomolecules. 2018 Oct 25;8(4). pii: E124. doi: 10.3390/biom8040124. Review.

8.

Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.

Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB.

Cancer. 2019 Jan 1;125(1):18-44. doi: 10.1002/cncr.31719. Epub 2018 Oct 3. Review. Erratum in: Cancer. 2019 Aug 1;125(15):2706.

PMID:
30281145
9.

Selenium unmasks protective iron armor: A possible defense against cutaneous inflammation and cancer.

Arbiser JL, Bonner MY, Ward N, Elsey J, Rao S.

Biochim Biophys Acta Gen Subj. 2018 May 28. pii: S0304-4165(18)30150-8. doi: 10.1016/j.bbagen.2018.05.018. [Epub ahead of print]

PMID:
29852199
10.

ROS modifiers and NOX4 affect the expression of the survivin-associated radio-adaptive response.

Murley JS, Arbiser JL, Weichselbaum RR, Grdina DJ.

Free Radic Biol Med. 2018 Aug 1;123:39-52. doi: 10.1016/j.freeradbiomed.2018.04.547. Epub 2018 Apr 13.

PMID:
29660403
11.

Targeting the Plasticity of Psoriasis.

Arbiser JL, Elsey J.

J Invest Dermatol. 2018 Apr;138(4):734-736. doi: 10.1016/j.jid.2017.11.030.

12.

Diablo: A Double-Edged Sword in Cancer?

Arbiser JL.

Mol Ther. 2018 Mar 7;26(3):678-679. doi: 10.1016/j.ymthe.2018.02.004. Epub 2018 Feb 20. No abstract available.

13.

Salivary levels of angiopoietin-2 in infants with infantile haemangiomas treated with and without systemic propranolol.

Seamens A, Nieman E, Losavio K, Bradley B, Nelson K, Chen KH, Chen S, Arbiser J, Lawley LP.

Exp Dermatol. 2018 Jun;27(6):636-640. doi: 10.1111/exd.13510. Epub 2018 Apr 3.

PMID:
29427463
14.

Honokiol is a FOXM1 antagonist.

Halasi M, Hitchinson B, Shah BN, Váraljai R, Khan I, Benevolenskaya EV, Gaponenko V, Arbiser JL, Gartel AL.

Cell Death Dis. 2018 Jan 24;9(2):84. doi: 10.1038/s41419-017-0156-7.

15.

Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target.

Pleniceanu O, Shukrun R, Omer D, Vax E, Kanter I, Dziedzic K, Pode-Shakked N, Mark-Daniei M, Pri-Chen S, Gnatek Y, Alfandary H, Varda-Bloom N, Bar-Lev DD, Bollag N, Shtainfeld R, Armon L, Urbach A, Kalisky T, Nagler A, Harari-Steinberg O, Arbiser JL, Dekel B.

EMBO Mol Med. 2017 Dec;9(12):1763. doi: 10.15252/emmm.201708507. No abstract available.

16.

Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin.

Wang X, Beitler JJ, Huang W, Chen G, Qian G, Magliocca K, Patel MR, Chen AY, Zhang J, Nannapaneni S, Kim S, Chen Z, Deng X, Saba NF, Chen ZG, Arbiser JL, Shin DM.

Clin Cancer Res. 2018 Feb 15;24(4):858-869. doi: 10.1158/1078-0432.CCR-17-0345. Epub 2017 Nov 27.

17.

Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol.

Pearson HE, Iida M, Orbuch RA, McDaniel NK, Nickel KP, Kimple RJ, Arbiser JL, Wheeler DL.

Mol Cancer Ther. 2018 Jan;17(1):204-214. doi: 10.1158/1535-7163.MCT-17-0384. Epub 2017 Oct 20.

18.

Honokiol Increases CD4+ T Cell Activation and Decreases TNF but Fails to Improve Survival Following Sepsis.

Klingensmith NJ, Chen CW, Liang Z, Burd EM, Farris AB, Arbiser JL, Ford ML, Coopersmith CM.

Shock. 2018 Aug;50(2):178-186. doi: 10.1097/SHK.0000000000001021.

19.

Promoting intolerance: learning from warts.

Rao S, Arbiser JL.

Br J Dermatol. 2017 Sep;177(3):621-622. doi: 10.1111/bjd.15613. No abstract available.

20.

Evidence for biochemical barrier restoration: Topical solenopsin analogs improve inflammation and acanthosis in the KC-Tie2 mouse model of psoriasis.

Arbiser JL, Nowak R, Michaels K, Skabytska Y, Biedermann T, Lewis MJ, Bonner MY, Rao S, Gilbert LC, Yusuf N, Karlsson I, Fritz Y, Ward NL.

Sci Rep. 2017 Sep 11;7(1):11198. doi: 10.1038/s41598-017-10580-y.

21.

Regression of diffuse B-cell lymphoma of the leg with intralesional gentian violet.

Rao S, Morris R, Rice ZP, Arbiser JL.

Exp Dermatol. 2018 Jan;27(1):93-95. doi: 10.1111/exd.13418. Epub 2017 Nov 7.

22.

Targeting the duality of cancer.

Arbiser JL, Bonner MY, Gilbert LC.

NPJ Precis Oncol. 2017;1. pii: 23. doi: 10.1038/s41698-017-0026-x. Epub 2017 Jun 22.

23.

Treatment of Hailey-Hailey Disease With Low-Dose Naltrexone.

Albers LN, Arbiser JL, Feldman RJ.

JAMA Dermatol. 2017 Oct 1;153(10):1018-1020. doi: 10.1001/jamadermatol.2017.2446. Erratum in: JAMA Dermatol. 2017 Oct 1;153(10):1072.

24.

Comprehensive profiling of H-Ras signalling in angiosarcoma endothelium.

da Costa A, Bonner M, Arbiser JL.

Clin Exp Dermatol. 2017 Aug;42(6):645-647. doi: 10.1111/ced.13149. Epub 2017 Jul 10.

PMID:
28691211
25.

Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells.

Metts J, Bradley HL, Wang Z, Shah NP, Kapur R, Arbiser JL, Bunting KD.

Sci Rep. 2017 Jun 30;7(1):4447. doi: 10.1038/s41598-017-04796-1.

26.

Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3.

Sengupta S, Nagalingam A, Muniraj N, Bonner MY, Mistriotis P, Afthinos A, Kuppusamy P, Lanoue D, Cho S, Korangath P, Shriver M, Begum A, Merino VF, Huang CY, Arbiser JL, Matsui W, Győrffy B, Konstantopoulos K, Sukumar S, Marignani PA, Saxena NK, Sharma D.

Oncogene. 2017 Oct 12;36(41):5709-5721. doi: 10.1038/onc.2017.164. Epub 2017 Jun 5.

27.

Activation of Protein Kinase C ε in Merkel Cell Polyomavirus-Induced Merkel Cell Carcinoma.

Costa A, Mackelfresh J, Gilbert L, Bonner MY, Arbiser JL.

JAMA Dermatol. 2017 Sep 1;153(9):931-932. doi: 10.1001/jamadermatol.2017.1296. No abstract available.

28.

Disruption of mitochondrial electron transport chain function potentiates the pro-apoptotic effects of MAPK inhibition.

Trotta AP, Gelles JD, Serasinghe MN, Loi P, Arbiser JL, Chipuk JE.

J Biol Chem. 2017 Jul 14;292(28):11727-11739. doi: 10.1074/jbc.M117.786442. Epub 2017 May 25.

29.

HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers.

Zhao L, Fan J, Xia S, Pan Y, Liu S, Qian G, Qian Z, Kang HB, Arbiser JL, Pollack BP, Kudchadkar RR, Lawson DH, Rossi M, Abdel-Wahab O, Merghoub T, Khoury HJ, Khuri FR, Boise LH, Lonial S, Chen F, Chen J, Lin R.

J Biol Chem. 2017 Jun 16;292(24):10142-10152. doi: 10.1074/jbc.M117.788778. Epub 2017 May 3.

30.

Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice.

Pillai VB, Kanwal A, Fang YH, Sharp WW, Samant S, Arbiser J, Gupta MP.

Oncotarget. 2017 May 23;8(21):34082-34098. doi: 10.18632/oncotarget.16133.

31.

Erratum to: Honokiol activates AMP-activated protein kinase in breast cancer cells via LKB1-dependent pathway and inhibits breast carcinogenesis.

Nagalingam A, Arbiser JL, Bonner MY, Saxena NK, Sharma D.

Breast Cancer Res. 2017 Mar 28;19(1):39. doi: 10.1186/s13058-017-0829-2. No abstract available.

32.

Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target

Pleniceanu O, Shukrun R, Omer D, Vax E, Kanter I, Dziedzic K, Pode-Shakked N, Mark-Daniei M, Pri-Chen S, Gnatek Y, Alfandary H, Varda-Bloom N, Bar-Lev DD, Bollag N, Shtainfeld R, Armon L, Urbach A, Kalisky T, Nagler A, Harari-Steinberg O, Arbiser JL, Dekel B.

EMBO Mol Med. 2017 Apr;9(4):508-530. doi: 10.15252/emmm.201506111. Erratum in: EMBO Mol Med. 2017 Dec;9(12 ):1763.

33.

Honokiol protects skin cells against inflammation, collagenolysis, apoptosis, and senescence caused by cigarette smoke damage.

Costa A, Facchini G, Pinheiro ALTA, da Silva MS, Bonner MY, Arbiser J, Eberlin S.

Int J Dermatol. 2017 Jul;56(7):754-761. doi: 10.1111/ijd.13569. Epub 2017 Feb 22.

34.

Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth.

Xia S, Lin R, Jin L, Zhao L, Kang HB, Pan Y, Liu S, Qian G, Qian Z, Konstantakou E, Zhang B, Dong JT, Chung YR, Abdel-Wahab O, Merghoub T, Zhou L, Kudchadkar RR, Lawson DH, Khoury HJ, Khuri FR, Boise LH, Lonial S, Lee BH, Pollack BP, Arbiser JL, Fan J, Lei QY, Chen J.

Cell Metab. 2017 Feb 7;25(2):358-373. doi: 10.1016/j.cmet.2016.12.010. Epub 2017 Jan 12.

35.

Double Jeopardy: The Rubber Ball Bounces Twice.

Arbiser JL, Gilbert LC.

J Invest Dermatol. 2017 Jan;137(1):15-17. doi: 10.1016/j.jid.2016.08.011. Review.

36.

Factors Influencing Prescription Drug Costs in the United States.

Arbiser JL.

JAMA. 2016 Dec 13;316(22):2430-2431. doi: 10.1001/jama.2016.17290. No abstract available.

PMID:
27959990
37.

SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis.

Akamata K, Wei J, Bhattacharyya M, Cheresh P, Bonner MY, Arbiser JL, Raparia K, Gupta MP, Kamp DW, Varga J.

Oncotarget. 2016 Oct 25;7(43):69321-69336. doi: 10.18632/oncotarget.12504.

38.

Effective local anesthesia for onabotulinumtoxin A injections to treat hyperhidrosis associated with traumatic amputation.

Shi LL, Sargen MR, Chen SC, Arbiser JL, Pollack BP.

Dermatol Online J. 2016 Jun 15;22(6). pii: 13030/qt38b203d0.

PMID:
27617615
39.

Pro-Apoptotic Activity of New Honokiol/Triphenylmethane Analogues in B-Cell Lymphoid Malignancies.

Mędra A, Witkowska M, Majchrzak A, Cebula-Obrzut B, Bonner MY, Robak T, Arbiser JL, Smolewski P.

Molecules. 2016 Jul 30;21(8). pii: E995. doi: 10.3390/molecules21080995.

40.

Improvement of "En Coup de Sabre" Morphea and Associated Headaches With Botulinum Toxin Injections.

Rimoin L, Arbiser J.

Dermatol Surg. 2016 Oct;42(10):1216-9. doi: 10.1097/DSS.0000000000000812. No abstract available.

PMID:
27465255
41.

Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia.

Laidlaw KM, Berhan S, Liu S, Silvestri G, Holyoake TL, Frank DA, Aggarwal B, Bonner MY, Perrotti D, Jørgensen HG, Arbiser JL.

Oncotarget. 2016 Aug 9;7(32):51651-51664. doi: 10.18632/oncotarget.10541.

42.

Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model.

Díaz B, Ostapoff KT, Toombs JE, Lo J, Bonner MY, Curatolo A, Adsay V, Brekken RA, Arbiser JL.

Oncotarget. 2016 Aug 9;7(32):51569-51580. doi: 10.18632/oncotarget.10514.

43.

Treatment of extensive erythema multiforme with topical gentian violet.

Murthy RK, Van L, Arbiser JL.

Exp Dermatol. 2017 May;26(5):431-432. doi: 10.1111/exd.13140. Epub 2017 Jan 12.

PMID:
27376564
44.

Down-Regulation of SOX2 Underlies the Inhibitory Effects of the Triphenylmethane Gentian Violet on Melanoma Cell Self-Renewal and Survival.

Pietrobono S, Morandi A, Gagliardi S, Gerlini G, Borgognoni L, Chiarugi P, Arbiser JL, Stecca B.

J Invest Dermatol. 2016 Oct;136(10):2059-2069. doi: 10.1016/j.jid.2016.06.610. Epub 2016 Jun 29.

45.

Gentian Violet: Bench-to-Bedside Research That Lowers Healthcare Costs.

Arbiser JL.

Skinmed. 2016 Apr 1;14(2):91-2. eCollection 2016. No abstract available.

PMID:
27319950
46.

Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells.

Kay NE, Sassoon T, Secreto C, Sinha S, Shanafelt TD, Ghosh AK, Arbiser JL.

Leuk Lymphoma. 2016 Oct;57(10):2409-16. doi: 10.3109/10428194.2016.1161186. Epub 2016 May 17.

47.

Use of Polyphenolic Compounds in Dermatologic Oncology.

Costa A, Bonner MY, Arbiser JL.

Am J Clin Dermatol. 2016 Aug;17(4):369-85. doi: 10.1007/s40257-016-0193-5. Review.

48.

Enhanced Clearance of Pseudomonas aeruginosa by Peroxisome Proliferator-Activated Receptor Gamma.

Bedi B, Yuan Z, Joo M, Zughaier SM, Goldberg JB, Arbiser JL, Hart CM, Sadikot RT.

Infect Immun. 2016 Jun 23;84(7):1975-1985. doi: 10.1128/IAI.00164-16. Print 2016 Jul.

49.

Inhibition of FoxM1-Mediated DNA Repair by Imipramine Blue Suppresses Breast Cancer Growth and Metastasis.

Rajamanickam S, Panneerdoss S, Gorthi A, Timilsina S, Onyeagucha B, Kovalskyy D, Ivanov D, Hanes MA, Vadlamudi RK, Chen Y, Bishop AJ, Arbiser JL, Rao MK.

Clin Cancer Res. 2016 Jul 15;22(14):3524-36. doi: 10.1158/1078-0432.CCR-15-2535. Epub 2016 Feb 29.

50.

Seborrheic Keratoses: The Rodney Dangerfield of Skin lesions, and Why They Should Get Our Respect.

Arbiser JL, Bonner MY.

J Invest Dermatol. 2016 Mar;136(3):564-566. doi: 10.1016/j.jid.2015.12.019.

Supplemental Content

Loading ...
Support Center